Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Low-level BCR-ABL1 transcripts in individuals without overt hematologic malignancy.

Leeman-Neill RJ, Swerdlow SH, Burnes CL, Melan MA, Nikiforova MN, Surti U, Aggarwal N.

Leuk Res. 2019 Jun;81:98-101. doi: 10.1016/j.leukres.2019.04.009. Epub 2019 Apr 22. No abstract available.

PMID:
31047698
2.

The Common Key to Class-Switch Recombination and Somatic Hypermutation: Discovery of AID and Its Role in Antibody Gene Diversification.

Leeman-Neill RJ, Lim J, Basu U.

J Immunol. 2018 Nov 1;201(9):2527-2529. doi: 10.4049/jimmunol.1801246. No abstract available.

3.

Pathogenesis of Enteropathy-Associated T Cell Lymphoma.

Chander U, Leeman-Neill RJ, Bhagat G.

Curr Hematol Malig Rep. 2018 Aug;13(4):308-317. doi: 10.1007/s11899-018-0459-5. Review.

PMID:
29943210
4.

BCL6 as a therapeutic target for lymphoma.

Leeman-Neill RJ, Bhagat G.

Expert Opin Ther Targets. 2018 Feb;22(2):143-152. doi: 10.1080/14728222.2018.1420782. Epub 2018 Jan 4. Review.

PMID:
29262721
5.

Fatal Case of Primary Cutaneous Aggressive T-Cell Lymphoma Switching From a CD4+ to a CD8+ Phenotype: Progressive Disease With Bexarotene and Romidepsin Treatment.

Johnson WT, Leeman-Neill RJ, Patel P, Ho J, Grandinetti LM, Jedrych J, Craig FE.

Am J Dermatopathol. 2016 Nov;38(11):832-837.

PMID:
27322928
6.

Histopathological features of papillary thyroid carcinomas detected during four screening examinations of a Ukrainian-American cohort.

Bogdanova TI, Zurnadzhy LY, Nikiforov YE, Leeman-Neill RJ, Tronko MD, Chanock S, Mabuchi K, Likhtarov IA, Kovgan LM, Drozdovitch V, Little MP, Hatch M, Zablotska LB, Shpak VM, McConnell RJ, Brenner AV.

Br J Cancer. 2015 Dec 1;113(11):1556-64. doi: 10.1038/bjc.2015.372. Epub 2015 Dec 3.

7.

Proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma have enhanced expression of MYC protein, which does not result from rearrangement or gain of the MYC gene.

Gibson SE, Leeman-Neill RJ, Jain S, Piao W, Cieply KM, Swerdlow SH.

Br J Haematol. 2016 Oct;175(1):173-5. doi: 10.1111/bjh.13844. Epub 2015 Nov 16. No abstract available.

PMID:
26568397
8.

ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer.

Leeman-Neill RJ, Kelly LM, Liu P, Brenner AV, Little MP, Bogdanova TI, Evdokimova VN, Hatch M, Zurnadzy LY, Nikiforova MN, Yue NJ, Zhang M, Mabuchi K, Tronko MD, Nikiforov YE.

Cancer. 2014 Mar 15;120(6):799-807. doi: 10.1002/cncr.28484. Epub 2013 Dec 10.

9.

RET/PTC and PAX8/PPARĪ³ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics.

Leeman-Neill RJ, Brenner AV, Little MP, Bogdanova TI, Hatch M, Zurnadzy LY, Mabuchi K, Tronko MD, Nikiforov YE.

Cancer. 2013 May 15;119(10):1792-9. doi: 10.1002/cncr.27893. Epub 2013 Feb 21.

10.

Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma.

Leeman-Neill RJ, Seethala RR, Singh SV, Freilino ML, Bednash JS, Thomas SM, Panahandeh MC, Gooding WE, Joyce SC, Lingen MW, Neill DB, Grandis JR.

Cancer Prev Res (Phila). 2011 Feb;4(2):230-7. doi: 10.1158/1940-6207.CAPR-10-0249. Epub 2010 Dec 16.

11.

Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation.

Wheeler SE, Suzuki S, Thomas SM, Sen M, Leeman-Neill RJ, Chiosea SI, Kuan CT, Bigner DD, Gooding WE, Lai SY, Grandis JR.

Oncogene. 2010 Sep 16;29(37):5135-45. doi: 10.1038/onc.2009.279. Epub 2010 Jul 12.

12.

Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.

Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR.

Clin Cancer Res. 2010 May 1;16(9):2571-9. doi: 10.1158/1078-0432.CCR-10-0333. Epub 2010 Apr 13.

13.

Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3.

Leeman-Neill RJ, Wheeler SE, Singh SV, Thomas SM, Seethala RR, Neill DB, Panahandeh MC, Hahm ER, Joyce SC, Sen M, Cai Q, Freilino ML, Li C, Johnson DE, Grandis JR.

Carcinogenesis. 2009 Nov;30(11):1848-56. doi: 10.1093/carcin/bgp211. Epub 2009 Sep 16.

14.

Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.

Li C, Zang Y, Sen M, Leeman-Neill RJ, Man DS, Grandis JR, Johnson DE.

Mol Cancer Ther. 2009 Aug;8(8):2211-20. doi: 10.1158/1535-7163.MCT-09-0327. Epub 2009 Jul 28.

Supplemental Content

Loading ...
Support Center